Eating ability in head and neck cancer patients after treatment with chemoradiation: A 12-month follow-up study accounting for dropout

Head & Neck ◽  
2003 ◽  
Vol 25 (12) ◽  
pp. 1034-1041 ◽  
Author(s):  
Alfred W. Rademaker ◽  
Edward F. Vonesh ◽  
Jeri A. Logemann ◽  
Barbara Roa Pauloski ◽  
Dachao Liu ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Follow Up Study

Follow-up of head and neck cancer patients post-radiotherapy

2003 ◽  
Vol 66 (3) ◽  
pp. 323-326 ◽  
Author(s):  
William P. O'Meara ◽  
Jon K. Thiringer ◽  
Peter A.S. Johnstone
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer

scholarly journals Anxiety and depression in patients with head and neck cancer: 6-month follow-up study

2016 ◽  
pp. 1029 ◽  
Author(s):  
Yi-Shan Wu ◽  
Pao-Yen Lin ◽  
Chih-Yen Chien ◽  
Fu-Min Fang ◽  
Nien-Mu Chiu ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Anxiety And Depression ◽  
Follow Up Study

A comparative study of the response and toxicities in locally advanced head and neck cancer patients treated with paclitaxel, cisplatinum, 5-FU versus docetaxel, cisplatinum, 5-FU as neoadjuvant chemotherapy followed by concurrent chemoradiation.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6089-6089
Author(s):  
Diptirani Samanta ◽  
Surendra nath Senapati ◽  
Kirti Ranjan Mohanty ◽  
Saroj Das
Keyword(s):  
Head And Neck Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Concurrent Chemoradiation ◽  
Advanced Head ◽  
Grade Ii

6089 Background: To evaluate the response and toxicity of docetaxel, cisplatinum, 5-FU vs paclitaxel, cisplatinum, 5-FU as neoadjuvant chemotherapy (NACT) followed by concurrent chemoradiation (CTRT) with weekly cisplatinum in locally advanced head and neck cancer. Methods: 40 locally advanced head and neck cancer patients who satisfied the eligibility criteria were randomized.21 patients received three cycles of NACT i.e paclitaxel (175 mg/m2) on d1, cisplatinum (30 mg/m2) and 5-FU (600 mg/m2) d2-d4 (TCF) and 19 patients received three cycles of NACT docetaxel (75 mg/m2) on d1, cisplatinum (30 mg/m2) and 5-FU (600 mg/m2) d2-d4 at three week intervals, followed by concurrent weekly cisplatinum 30 mg/m2 along with conventional external beam radiation of total tumor dose dose 66 Gy. Response was assessed after NACT and again after six weeks, three months and six months of completion of chemoradiation. Toxicities were assessed after each cycles of NACT and also weekly during CTRT and thereafter. Results: Two weeks after completion of NACT complete response (CR) in TCF was 4.76%, partial response (PR) 80.9% and no response 9.5%. However in DCF, CR was 15.78 % PR was 73.68%. 10.52% patientd died due to toxicity. With a median follow up of seven months, in TCF CR was 57.14%, PR 33.33% and no response was 4.76%, whereas in DCF CR was 78.94%, PR 10.52% and death 10.5%. On evaluation of toxicities during NACT, patients in DCF had more significant neutropenia and in TCF more incidence of neuropathy. During CTRT, in TCF grade II and III mucositis was 54%, grade II neutropenia 5.6%, and grade II anemia 5.3%. In DCF mucositis grade II and III was 49.0%, neutropenia grade II 18.7% and anemia grade II was 7.4%. Late toxicities included were comparable in both arms. Conclusions: With a median follow up of 7 months, the CR in DCF was 78.94%, superior than TCF i.e 57.14%. Neutropenia was significant in DCF and neuropathy was high in TCF. In CTRT mucositis was the commonest toxicity observed in both TCF and DCF which was not statistically significant.

The Importance of Long-term Follow-up of Head and Neck Cancer Patients for Reliable Survival Analysis

2005 ◽  
Vol 133 (6) ◽  
pp. 877-881 ◽  
Author(s):  
Antonio Vitor Martins Priante ◽  
André Lopes Carvalho ◽  
Karina de Cássia Braga Ribeiro ◽  
Hirde Contesini ◽  
Luiz Paulo Kowalski
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Survival Time ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Survival Rates ◽  
Accurate Estimate ◽  
Upper Aerodigestive Tract ◽  
Lost To Follow Up

OBJECTIVE: Analyze the influence of patients lost to follow-up in estimated survival rates calculated by the Kaplan-Meier method. STUDY DESIGN: Only patients with previously untreated squamous cell carcinoma of the upper aerodigestive tract were selected. For the patients lost to follow-up anytime, the last medical evaluation date was collected to calculate the “estimate A” survival time. If the same patient returned to our outpatient clinic or further health information was obtained, the updated last information/evaluation date was also collected to calculate “estimate B” survival time. The survival curves considering “estimate A” and “B” survival rates were compared. RESULTS: The overall 5 and 10-years survival rates for all patients calculated for “estimate A” were 54.0% and 46.0%, respectively; compared with 42.8% and 28.2% when were calculated considering “estimate B” ( P < 0.001). CONCLUSION: Close follow-up of the head and neck cancer patients is essential for an accurate estimate of survival by KaplanMeier method. EBM RATING: C

Sign in / Sign up

Export Citation Format

Share Document